Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic review

• Published in: Breast cancer research and treatment 2012-07, Vol.134 (2), p.459-478
• Main Authors: Murphy, Caitlin C., Bartholomew, L. Kay, Carpentier, Melissa Y., Bluethmann, Shirley M., Vernon, Sally W.
• Format: Article
• Language: English
• Subjects: Adjuvant treatment; Antineoplastic Agents, Hormonal - therapeutic use; Biological and medical sciences; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Cancer; Cancer research; Cancer survivors; Cancer therapies; Care and treatment; Chemotherapy, Adjuvant; Clinical Trials as Topic; Cytochrome P-450; Endocrine therapy; Female; Gynecology. Andrology. Obstetrics; Health aspects; Health behavior; Humans; Mammary gland diseases; Medical sciences; Medication Adherence; Medicine; Medicine & Public Health; Neoplasms, Hormone-Dependent - drug therapy; Neoplasms, Hormone-Dependent - mortality; Oncology; Patient compliance; Review; Survivors; Systematic review; Tamoxifen; Tumors
• ISSN: 0167-6806; 1573-7217
• DOI: 10.1007/s10549-012-2114-5

Adjuvant hormonal therapy significantly improves long-term survival of breast cancer patients with hormone receptor-positive disease. Despite the proven clinical efficacy of tamoxifen and aromatase inhibitors, many breast cancer survivors either fail to take the correct dosage at the prescribed frequency (adherence) or discontinue therapy (persistence). This systematic review aims to: (1) determine the prevalence of adherence and persistence to adjuvant hormonal therapy among breast cancer survivors in clinical practice, and (2) identify correlates of adherence and persistence. We searched Medline, PubMed, PsycINFO, and CINAHL for studies that measured rates and/or correlates of adherence and/or persistence to adjuvant hormonal therapy. Studies were reviewed in a multi-step process: (1) the lead author screened titles and abstracts of all potentially eligible studies; (2) each coauthor reviewed a random 5 % sample of abstracts; and (3) two sets of coauthors each reviewed half of all “maybe” abstracts. Any disagreements were discussed until consensus was reached. Twenty-nine studies met inclusion criteria. Prevalence of adherence ranged from 41 to 72 % and discontinuation (i.e., nonpersistence) ranged from 31 to 73 %, measured at the end of 5 years of treatment. Extremes of age (older or younger), increasing out-of-pocket costs, follow-up care with a general practitioner (vs. oncologist), higher CYP2D6 activity, switching from one form of therapy to another, and treatment side effects were negatively associated with adherence and/or persistence. Taking more medications at baseline, referral to an oncologist, and earlier year at diagnosis were positively associated with adherence and/or persistence. Adherence and persistence to adjuvant hormonal therapy among breast cancer survivors is suboptimal. Many of the correlates of adherence and persistence studied to date are not modifiable. Our review reveals a critical need for further research on modifiable factors associated with adherence to adjuvant hormonal therapy, and the development of behavioral interventions to improve adherence in this population.